Stage 0a Bladder Cancer AJCC v8 Completed Phase 2 Trials for Erlotinib (DB00530)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0110521 (Stage 0a Bladder Cancer AJCC v8) | Completed | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT00749892 | Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer | Treatment |